Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 3-10

  Tang, Xiaoqiang ^a,b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; Diagnosis; Prognosis; Tumor associated macrophage

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD14 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CHEMOKINE; COLONY STIMULATING FACTOR 1; CXCL18 CHEMOKINE; CYCLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FERRITIN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE RECEPTOR; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ADJUVANT THERAPY; BREAST BIOPSY; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS FREE SURVIVAL; NEUTROPHIL CHEMOTAXIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; SHORT SURVEY; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84875253893     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.024     Document Type: Review

References (89)

1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA. Cancer J. Clin. 2011, 61:408-418.
2. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., Mandelblatt J.S., Yakovlev A.Y., Habbema J.D.F., Feuer E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl. J. Med. 2005, 353:1784-1792.
3. Polyak K. Heterogeneity in breast cancer. J. Clin. Invest. 2011, 121:3786-3788.
4. Ruiz-Narváez E.A., Rosenberg L., Yao S., Rotimi C.N., Cupples L.A., Bandera E.V., Ambrosone C.B., Adams-Campbell L.L., Palmer J.R. Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African American women. Carcinogenesis 2012, http://dx.doi.org/10.1093/carcin/bgs334.
5. Fernandez-Navarro P., Pita G., Santamariña C., Moreno M.P., Vidal C., Miranda-García J., Ascunce N., Casanova F., Collado-García F., Herráez B., González-Neira A., Benítez J., Pollán M. Association analysis between breast cancer genetic variants and mammographic density in a large population-based study (Determinants of Density in Mammographies in Spain) identifies susceptibility loci in TOX3 gene. Eur. J. Cancer 2013, 49:474-481.
6. Cowper-Sallari R., Zhang X., Wright J.B., Bailey S.D., Cole M.D., Eeckhoute J., Moore J.H., Lupien M. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 2012, 44:1191-1198.
7. Stevens K.N., Wang X., Fredericksen Z., Pankratz V.S., Greene M.H., Andrulis I.L., Thomassen M., Caligo M., Nathanson K.L., Jakubowska A. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res. Treat. 2012, 136:295-302.
8. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukocyte Biol. 2008, 84:623-630.
9. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
10. Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 2008, 180:2011-2017.
11. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
12. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
13. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
14. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
15. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
16. Ojalvo L.S., Whittaker C.A., Condeelis J.S., Pollard J.W. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J. Immunol. 2010, 184:702-712.
17. Egeblad M., Ewald A.J., Askautrud H.A., Truitt M.L., Welm B.E., Bainbridge E., Peeters G., Krummel M.F., Werb Z. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model Mech. 2008, 1:155-167.
18. Laoui D., Movahedi K., Van Overmeire E., Van Den Bossche J., Schouppe E., Mommer C., Nikolaou A., Morias Y., Baetselier P.D., Van Ginderachter J.A. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int. J. Dev. Biol. 2011, 55:861-867.
19. Leek R.D., Harris A.L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7:177-189.
20. Mukhtar R.A., Nseyo O., Campbell M.J., Esserman L.J. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev. Mol. Diagn. 2011, 11:91-100.
21. Laoui D., Movahedi K., Van Overmeire E., Van den Bossche J., Schouppe E., Mommer C., Nikolaou A., Morias Y., De Baetselier P., Van Ginderachter J.A. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int. J. Dev. Biol. 2011, 55:861-867.
22. Tang X., Mo C., Wang Y., Wei D., Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013, 138:93-104.
23. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.-H., Dolman C., Markowitz D., Wu W., Liu C., Reisfeld R.A., Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 2006, 116:2132-2141.
24. Galmbacher K., Heisig M., Hotz C., Wischhusen J., Galmiche A., Bergmann B., Gentschev I., Goebel W., Rapp U.R., Fensterle J. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS ONE 2010, 5:e9572.
25. Eubank T.D., Roberts R.D., Khan M., Curry J.M., Nuovo G.J., Kuppusamy P., Marsh C.B. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res. 2009, 69:2133-2140.
26. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., Coussens L.M., Karin M., Goldrath A.W., Johnson R.S. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70:7465-7475.
27. Yamamoto N., Suyama H., Yamamoto N., Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int. J. Cancer 2008, 122:461-467.
28. Wood G.W., Gollahon K.A. Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell-surface markers. J. Natl. Cancer Inst. 1977, 59:1081-1087.
29. Steele R.J., Brown M., Eremin O. Characterisation of macrophages infiltrating human mammary carcinomas. Br. J. Cancer 1985, 51:135-138.
30. Kelly P.M.A., Davison R.S., Bliss E., McGee J.O.D. Macrophages in human breast disease: a quantitative immunohistochemical study. Br. J. Cancer 1988, 57:174-177.
31. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2796-2801.
32. Gottfried E., Kunz-Schughart L.A., Weber A., Rehli M., Peuker A., Müller A., Kastenberger M., Brockhoff G., Andreesen R., Kreutz M. Expression of CD68 in non-myeloid cell types. Scand. J. Immunol. 2008, 67:453-463.
33. Misago N., Satoh T., Narisawa Y. Cellular neurothekeoma with histiocytic differentiation. J. Cutan. Pathol. 2004, 31:568-572.
34. Groisman G.M., Amar M., Schäfer I. The histiocytic marker PG-M1 is helpful in differentiating histiocytes and histiocytic tumors from melanomas. Appl. Immunohisto. Mol. Morphol. 2002, 10:205-209.
35. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
36. Jubb A.M., Soilleux E.J., Turley H., Steers G., Parker A., Low I., Blades J., Li J.-L., Allen P., Leek R., Noguera-Troise I., Gatter K.C., Thurston G., Harris A.L. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am. J. Pathol. 2010, 176:2019-2028.
37. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 2005, 14:425-431.
38. Mahmoud S.M.A., Lee A.H.S., Paish E.C., Macmillan R.D., Ellis I.O., Green A.R. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J. Clin. Pathol. 2012, 65:159-163.
39. Jézéquel P., Campion L., Spyratos F., Loussouarn D., Campone M., Guérin-Charbonnel C., Joalland M.-P., André J., Descotes F., Grenot C., Roy P., Carlioz A., Martin P.-M., Chassevent A., Jourdan M.-L., Ricolleau G. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int. J. Cancer 2012, 131:426-437.
40. Perez E.A. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist 2011, 16:20-22.
41. Breast Cancer Facts & Figures, 2011-2012. http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012.
42. Volodko N., Reiner A., Rudas M., Jakesz R. Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 1998, 7:99-105.
43. Vicioso L., Gonzalez F.J., Alvarez M., Ribelles N., Molina M., Marquez A., Perez L., Matilla A., Alba E. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am. J. Clin. Pathol. 2006, 125:111-118.
44. Campbell M., Tonlaar N., Garwood E., Huo D., Moore D., Khramtsov A., Au A., Baehner F., Chen Y., Malaka D., Lin A., Adeyanju O., Li S., Gong C., McGrath M., Olopade O., Esserman L. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat. 2011, 128:703-711.
45. Mukhtar R., Moore A., Nseyo O., Baehner F., Au A., Moore D., Twomey P., Campbell M., Esserman L. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-caucasian ethnicity. Breast Cancer Res. Treat. 2011, 130:635-644.
46. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., Liu B., Deng H., Wang F., Lin L., Yao H., Su F., Anderson Karen S., Liu Q., Ewen Mark E., Yao X., Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
47. Murri A.M.A., Hilmy M., Bell J., Wilson C., McNicol A.M., Lannigan A., Doughty J.C., McMillan D.C. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br. J. Cancer 2008, 99:1013-1019.
48. Medrek C., Ponten F., Jirstrom K., Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12:306.
49. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirström K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
50. Jinushi M., Chiba S., Yoshiyama H., Masutomi K., Kinoshita I., Dosaka-Akita H., Yagita H., Takaoka A., Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. USA 2011, 108:12425-12430.
51. Shree T., Olson O.C., Elie B.T., Kester J.C., Garfall A.L., Simpson K., Bell-McGuinn K.M., Zabor E.C., Brogi E., Joyce J.A. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
52. Yang J., Liao D., Chen C., Liu Y., Chuang T.-H., Xiang R., Markowitz D., Reisfeld R.A., Luo Y. Tumor associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2012, http://dx.doi.org/10.1002/stem.12.
53. Meng Y., Beckett M.A., Liang H., Mauceri H.J., van Rooijen N., Cohen K.S., Weichselbaum R.R. Blockade of tumor necrosis factor α signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010, 70:1534-1543.
54. Visscher D.W., Tabaczka P., Long D., Crissman J.D. Clinicopathologic analysis of macrophage infiltrates in breast carcinoma. Pathol. Res. Pract. 1995, 191:1133-1139.
55. Bolat F., Kayaselcuk F., Nursal T.Z., Yagmurdur M.C., Bal N., Demirhan B. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J. Exp. Clin. Cancer Res. 2006, 25:365-372.
56. Shabo I., Stål O., Olsson H., Doré S., Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int. J. Cancer 2008, 123:780-786.
57. Leek R.D., Hunt N.C., Landers R.J., Lewis C.E., Royds J.A., Harris A.L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000, 190:430-436.
58. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67:5064-5066.
59. Foekens J.A., Peters H.A., Grebenchtchikov N., Look M.P., Meijer-van Gelder M.E., Geurts-Moespot A., van der Kwast T.H., Sweep C.G.J., Klijn J.G.M. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001, 61:5407-5414.
60. Valković T., Dobrila F., Melato M., Sasso F., Rizzardi C., Jonjić N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002, 440:583-588.
61. Lewis J.S., Landers R.J., Underwood J.C.E., Harris A.L., Lewis C.E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 2000, 192:150-158.
62. Gasparini G., Fox S.B., Verderio P., Bonoldi E., Bevilacqua P., Boracchi P., Dante S., Marubini E., Harris A.L. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin. Cancer. Res. 1996, 2:1191-1198.
63. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Association of tumor necrosis factor-a and its receptors with thymidine phosphorylase expression in invasive breast-carcinoma. Br. J. Cancer 1999, 79:991-995.
64. Murdoch C., Lewis C.E. Macrophage migration and gene expression in response to tumor hypoxia. Int. J. Cancer 2005, 117:701-708.
65. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
66. Leek R.D., Talks K.L., Pezzella F., Turley H., Campo L., Brown N.S., Bicknell R., Taylor M., Gatter K.C., Harris A.L. Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 2002, 62:1326-1329.
67. Toi M., Ueno T., Matsumoto H., Saji H., Funata N., Koike M., Tominaga T. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin. Cancer. Res. 1999, 5:1131-1137.
68. Brown N.S., Jones A., Fujiyama C., Harris A.L., Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000, 60:6298-6302.
69. Mukhtar R.A., Moore A.P., Tandon V.J., Nseyo O., Twomey P., Adisa C.A., Eleweke N., Au A., Baehner F.L., Moore E.A.Dan H. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann. Surg. Oncol. 2012, 19:3979-3986.
70. Recalcati S., Locati M., Marini A., Santambrogio P., Zaninotto F., De Pizzol M., Zammataro L., Girelli D., Cairo G. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur. J. Immunol. 2010, 40:824-835.
71. Corna G., Campana L., Pignatti E., Castiglioni A., Tagliafico E., Bosurgi L., Campanella A., Brunelli S., Manfredi A.A., Apostoli P., Silvestri L., Camaschella C., Querini P.R. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 2010, 95:1814-1822.
72. Niméus E., Malmström J., Johnsson A., Marko-Varga G., Fernö M. Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. J. Pharm. Biomed. Anal. 2007, 43:1086-1093.
73. Nariţa D., Seclaman E., Ursoniu S., Ilina R., Cireap N., Anghel A. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom. J. Morphol. Embryol. 2011, 52:1261-1267.
74. Robinson B.D., Sica G.L., Liu Y.-F., Rohan T.E., Gertler F.B., Condeelis J.S., Jones J.G. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer. Res. 2009, 15:2433-2441.
75. Zohny S., Fayed S. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med. Oncol. 2010, 27:1246-1253.
76. Ch'ng E., Tuan Sharif S., Jaafar H. In human invasive breast ductal carcinoma, tumor stromal macrophages and tumor nest macrophages have distinct relationships with clinicopathological parameters and tumor angiogenesis. Virchows Arch. 2013, 1-11.
77. Wyckoff J.B., Wang Y., Lin E.Y., Li J.-f., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
78. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., Delaney A., Jones S.J., Iqbal J., Weisenburger D.D., Bast M.A., Rosenwald A., Muller-Hermelink H.-K., Rimsza L.M., Campo E., Delabie J., Braziel R.M., Cook J.R., Tubbs R.R., Jaffe E.S., Lenz G., Connors J.M., Staudt L.M., Chan W.C., Gascoyne R.D. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New Engl. J. Med. 2010, 362:875-885.
79. Ojalvo L.S., King W., Cox D., Pollard J.W. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 2009, 174:1048-1064.
80. Daldrup-Link H.E., Golovko D., Ruffell B., DeNardo D.G., Castaneda R., Ansari C., Rao J., Tikhomirov G.A., Wendland M.F., Corot C., Coussens L.M. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer. Res. 2011, 17:5695-5704.
81. Daldrup-Link H., Coussens L.M. MR imaging of tumor-associated macrophages. OncoImmunology 2012, 1:507-509.
82. Shih Y.-Y.I., Hsu Y.-H., Duong T.Q., Lin S.-S., Chow K.-P.N., Chang C. Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR Biomed. 2011, 24:1353-1360.
83. Yang L., Peng X.-H., Wang Y.A., Wang X., Cao Z., Ni C., Karna P., Zhang X., Wood W.C., Gao X., Nie S., Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer. Res. 2009, 15:4722-4732.
84. Melancon M.P., Lu W., Huang Q., Thapa P., Zhou D., Ng C., Li C. Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813. Biomaterials 2010, 31:6567-6573.
85. Movahedi K., Schoonooghe S., Laoui D., Houbracken I., Waelput W., Breckpot K., Bouwens L., Lahoutte T., De Baetselier P., Raes G., Devoogdt N., Van Ginderachter J.A. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012, 72:4165-4177.
86. Keliher E.J., Yoo J., Nahrendorf M., Lewis J.S., Marinelli B., Newton A., Pittet M.J., Weissleder R. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconj. Chem. 2011, 22:2383-2389.
87. Leimgruber A., Berger C., Cortez-Retamozo V., Etzrodt M., Newton A.P., Waterman P., Figueiredo J.L., Kohler R.H., Elpek N., Mempel T.R., Swirski F.K., Nahrendorf M., Weissleder R., Pittet M.J. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 2009, 11:459-468.
88. Verdoes M., Edgington Laura E., Scheeren F.A., Leyva M., Blum G., Weiskopf K., Bachmann Michael H., Ellman Jonathan A., Bogyo M. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem. Biol. 2011, 19:619-628.
89. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011, 9:216.